Blog
RSS FeedPosted by Michael Wonder on 21 Apr 2024
The myth of the free market for pharmaceuticals
20 April 2024 - Critics of US policy aiming to reduce spending on prescription drugs claim that the government is wrongfully ...
Posted by Michael Wonder on 19 Apr 2024
National pharmacare will reduce access to new medicines for 27 million privately insured Canadians
18 April 2024 - The federal Liberal-NDP coalition government recently announced it would work with the provinces to fund universal prescription ...
Posted by Michael Wonder on 10 Apr 2024
New target zero initiative aims to help improve access to new drugs
9 April 2024 - Target Zero is a new initiative that aims to improve the time to access for patients ...
Posted by Michael Wonder on 24 Feb 2024
Drug insurance: a single payer pharmacare program would jeopardise coverage quality for 21 million Canadians
22 February 2024 - Imposing a single payer universal drug insurance plan on all Canadians would jeopardise coverage quality for ...
Posted by Michael Wonder on 16 Nov 2023
Data sharing a a new era for research funded by the US Government
15 November 2023 - In January 2023, the NIH implemented its new Data Management and Sharing Policy. ...
Posted by Michael Wonder on 02 Nov 2023
Launch of the Australian Cancer Plan
2 November 2023 - Learn about the new Australian Cancer Plan, which aims to improve prevention, screening, treatment and management of ...
Posted by Michael Wonder on 22 Oct 2023
We need a public option for pharmaceuticals
20 October 2023 - America is currently facing dual public health crises of record drug shortages and skyrocketing prices. ...
Posted by Michael Wonder on 11 Sep 2023
Act’s productivity perspective on PHARMAC medication and treatments will hurt minorities
11 September 2023 - Act is proposing a “productivity perspective based on real lives” when it comes to delivering PHARMAC ...
Posted by Michael Wonder on 10 Aug 2023
How a controversial US drug policy could be harming cancer patients worldwide
9 August 2023 - The FDA’s accelerated approval process was designed to help people access life saving drugs. ...
Posted by Michael Wonder on 08 Aug 2023
How industrial policy could accelerate innovation in the life sciences
8 August 2023 - The US is expanding public investment in the technology-based industries, including the life sciences, in a move ...
Posted by Michael Wonder on 17 Jul 2023
Novel Alzheimer disease treatments and reconsideration of US pharmaceutical reimbursement policy
17 July 2023 - While donanemab appears to be among the first therapies to demonstrate measurable clinical benefit for Alzheimer's disease, ...
Posted by Michael Wonder on 07 Jul 2023
A priority review voucher program to fuel generic drug development
6 July 2023 - Millions of Americans report that they are unable to fill their prescriptions or are not taking their ...
Posted by Michael Wonder on 28 Jun 2023
Korea’s drug pricing policies for the second half of 2023
22 June 2023 - In the first half of 2023, the Ministry of Health and Welfare set up a public ...
Posted by Michael Wonder on 10 Jun 2023
A review of labeling based on patient reported outcome endpoints for new oncology drugs approved by the EMA (2017-2021)
9 June 2023 - A review of new oncology indications approved by the EMA for 2012-2016 showed that 33% of new ...
Posted by Michael Wonder on 12 Apr 2023
ASCO policy statement on biosimilar and interchangeable products in oncology
12 April 2023 - Given the current market dynamics and the regulatory landscape, this ASCO manuscript now seeks to propose several ...